Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo

Breaking barriers in lung cancer research

The fight against lung cancer is evolving, with groundbreaking research shedding light on the intricate interplay between biology, environment, and health disparities.

September 12, 2025

Vol.51 No.33

By Loretta Erhunmwunsee

Obituary

Bonnie Addario, lung cancer survivor and advocate, dies at 77

Bonnie J. Addario, a tireless advocate, died Aug. 25, leaving behind a legacy of love, leadership, and global impact. Bonnie was first and foremost devoted to her family—her husband of over 40 years, Tony; her children Danielle, Jared, and Andrea; her nine grandchildren; and five great-grandchildren. To all of them, she was the heart of...

September 12, 2025

Vol.51 No.33

By Neptune Society

In Brief

Montefiore Einstein’s lung cancer team earns international recognition

Montefiore Einstein CCC lung cancer teamMontefiore Einstein Comprehensive Cancer Center’s lung cancer team received the The Cancer Care Team Award from the International Association for the Study of Lung Cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows

Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.

September 12, 2025

Vol.51 No.33

Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo

YOU MAY BE INTERESTED IN

Breaking barriers in lung cancer research

Bonnie Addario, lung cancer survivor and advocate, dies at 77

Montefiore Einstein’s lung cancer team earns international recognition

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Renew today!

Subscriber content

Never miss an issue!

Login